The spectrum of yeasts and their antifungal susceptibility profile are poorly known and treatment of fungal disease has remained empirical. The aim of this study is to determine the spectrum and antifungal susceptibility profile of yeasts particularly of Candida species. A descriptive study on the composition of Candida species and antifungal susceptibility profile were conducted from January 2018 to September 2018. Clinical samples collected from different sites were cultured on Sabouraud dextrose agar and incubated for an appropriate time. Identification of yeast isolates and their antifungal susceptibility profile were determined by the VITEK 2 compact system. Descriptive statistics such as frequency and percentage of Candida species were calculated using SPSS version 20. Of 209 yeasts recovered, 104(49.8%), 90 (43.1%), 15(7.2%) were C. albicans, non albicans Candida species, and other yeasts, respectively. Among non albicans Candida species, Candida krusei was the commonest isolate. Of other yeast groups, 66.7% was represented by Cryptococcus laurentii. Regardless of Candida species identified, 85.6, 3.9, and 10.5% of the isolates were susceptible, intermediate, and resistant to fluconazole, respectively. C krusei was 100% resistant to the drug. Voriconazole demonstrated the greatest antifungal activity against Candida isolates in which 99.4% of Candida isolates were susceptible. The susceptibility and the resistance rate of Candida isolate to both caspofungin and micafungin were the same being 96 and 4% respectively. However, micafungin was more potent than caspofungin. The susceptibility, resistant, and intermediate rates of yeasts against flucytosine were, 86.2, 6.6, and 7.2%, respectively. The present study demonstrated the distribution of Candida species in different clinical specimens where the isolation rate of non-albicans Candida species was comparable to Candida albicans. The high resistance rate of C. krusei to fluconazole and flucytosine may demonstrate that the treatment of candidiasis empirically is questionable.

中文翻译：

---

埃塞俄比亚不同临床样本中分离出的白色念珠菌和非白色念珠菌的分布及其体外抗真菌药性。

酵母的光谱及其抗真菌药性状况鲜为人知，对真菌病的治疗仍是经验性的。这项研究的目的是确定酵母的光谱和抗真菌药性谱，尤其是念珠菌属的酵母。从2018年1月至2018年9月对念珠菌的成分和抗真菌药性进行了描述性研究。将从不同部位收集的临床样品在Sabouraud葡萄糖琼脂上培养并孵育适当的时间。酵母分离物的鉴定及其抗真菌药性谱由VITEK 2紧凑型系统确定。使用SPSS 20版计算描述性统计数据，例如念珠菌种类的频率和百分比。在回收的209个酵母中，有104（49.8％），90（43.1％），15（7.2％）是C。白色念珠菌，非白色念珠菌念珠菌和其他酵母菌。在非白色念珠菌种中，克鲁斯念珠菌是最常见的分离株。在其他酵母菌群中，劳伦隐球菌占66.7％。无论鉴定出哪种假丝酵母，分别有85.6、3.9和10.5％的分离株对氟康唑敏感，中等和耐药。克鲁斯酵母对这种药物有100％的耐药性。伏立康唑对念珠菌具有最大的抗真菌活性，其中99.4％的念珠菌易感。念珠菌分离株对卡泊芬净和米卡芬净的敏感性和耐药率相同，分别为96％和4％。但是，米卡芬净比卡泊芬净更有效。酵母对氟胞嘧啶的敏感性，抗性和中等率分别为86.2、6.6和7。分别为2％。本研究证明了念珠菌在不同临床标本中的分布，其中非白色念珠菌的分离率与白色念珠菌相当。克鲁斯克鲁维酵母对氟康唑和氟胞嘧啶的高耐药率可能表明，凭经验对念珠菌病的治疗存在疑问。